SEED INNOVATIONS LIMITED

Regulatory Filings • Jul 17, 2025

National Storage Mechanism | Additional information

RNS Number : 4630R

Seed Innovations Limited

17 July 2025

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

17 July 2025

SEED Innovations Limited

("SEED" or the "Company")

Divestment of Oxford BioDynamics Position

SEED Innovations Ltd, the AIM-quoted investment company providing retail investors with exposure to disruptive, high-growth life sciences and technology ventures typically inaccessible to them, announces the successful exit from its investment in AIM-quoted Oxford BioDynamics plc ("OBD") as part of its short-term trading strategy.

SEED originally invested £125,000 in OBD in February 2025 at 0.5p (£0.005) per share, funded from existing cash reserves. The Company has now exited its entire position, achieving an average sale price of 0.58p (£0.0058095) per share, generating gross proceeds of £145,237.50 (before brokerage costs) and delivering a net profit of approximately £20,000 (16%).

Ed McDermott, CEO of SEED Innovations, commented: "While it's always encouraging to make a profit, the holding period was longer than originally anticipated. In this instance, exiting the position after six months was a prudent risk management decision. To date, our short-term trading strategy has consistently delivered profitable outcomes and outperformed the returns that would have been achieved had the capital been allocated to traditional term deposits."

- Ends -

For further information on the Company please visit:   www.seedinnovations.co  or contact: 

Ed McDermott  Lance de Jersey	SEED Innovations Ltd	E:   info@seedinnovations.co
James Biddle  Roland Cornish	Beaumont   Cornish   Limited,  Nomad	T: (0)20 7628 3396
Isabella Pierre  Damon Heath	Shard Capital Partners LLP  Broker	T: (0)20 7186 9927
Ana Ribeiro Isabel de Salis	St Brides Partners Ltd,  Financial PR	E: seed@stbridespartners.co.uk

NOTES  

Seed Innovations Ltd  

Seed Innovations Ltd is an AIM quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors. Its strategy focuses on identifying early-stage opportunities with upcoming investment catalysts, alongside more mature investments providing near-term liquidity. With a portfolio of such investments and cash reserves, the Company is agile and poised to capitalise swiftly on new investment opportunities.

Market Abuse Regulation (MAR) Disclosure

The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulations (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR').

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUBVVRVUUBARR